Liqrev Suspension (sildenafil)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM): _____** **WEIGHT (LB/KG): _____** **ALLERGIES: _____**

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** DURATION OF THERAPY (SPECIFIC DATES):		**IF RENEWAL:** DATE THERAPY INITIATED:	

Continued on next page.

Liqrev Suspension (sildenafil)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
□ **Pulmonary arterial hypertension (PAH)** □ **Raynaud's phenomenon** □ **Diagnosis: _____ICD-10 Code(s): _____**	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Has patient tried and failed or has an absolute contraindication to generic sildenafil suspension? □ Yes □ No Please submit documentation.

For <u>pulmonary arterial hypertension</u>, answer the following:
Does the patient have a diagnosis of Group 1 pulmonary arterial hypertension (PAH)? □ Yes □ No Please submit documentation.

Select if the diagnosis of Group 1 pulmonary arterial hypertension (PAH) is caused by one of the follow ing etiologies:* Please submit documentation.
□ Chronic hemolytic anemia
□ Congenital heart disease (e.g., atrial-septal defect)
□ Associated with surgical repair of a congenital systemic-to-pulmonary shunt of at least 1year in duration(e.g., ventricular septal defect, patent ductus arteriosus)
□ Drugs and toxins induced (not reactive to acute vasoreactivity testing (AVT) or failed calcium channel blocker)CCB treatment)
□ HIV infection
□ Idiopathic/primary PAH
□ Portal hypertension
□ Schistosomiasis
□ Tissue disease (e.g., lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease)
Please provide documentation.

Does the patient have WHO functional class II, III, or IV?* □ Yes □ No
Please provide documentation.

Is patient's diagnosis confirmed by cardiac catheterization? □ Yes □ No

Does patient have, (at rest), measured by cardiac catheterization a mean pulmonary artery pressure(mPAP of 20mmHg or greater via right heart cath to confirm PAH? □ Yes □ No *Please provide documentation.*

Does patient have, (at rest), measured by cardiac catheterization a pulmonary capillary wedge pressure (PCWP) 15mmHg or less via right heart cath to confirm PAH? □ Yes □ No *Please provide documentation.*

Does patient have, (at rest), measured by cardiac catheterization a pulmonary vascular resistance (PVR) value equaling 3 wood units or greater via right heart cath to confirm PAH? □ Yes □ No *Please provide documentation.*

If patient has idiopathic PAH, hereditary PAH (excludes congenital heart disease like atrial=septal defect) or drug/toxin induced PAH, did patient have had an acute vasoreactivity test? □ Yes □ No *Please provide documentation.*

Has patient been previously treated with a Calcium channel blocker? □ Yes □ No *Please provide documentation.*

Select the prescribing physician's specialty:
□ Cardiology
□ Nephrology
□ Pulmonology
□ Rheumatology

Does patient have a history of left-sided heart disease? □ Yes □ No Please submit documentation.

Does patient have severe renal insufficiency? □ Yes □ No Please submit documentation.

Does patient have pulmonary hypertension related to conditions other than previously specified? □ Yes □ No

For Raynaud's phenomenon, answer the following:

Is the prescribing physician a rheumatologist? □ Yes □ No

Is the patient's Raynaud's phenomenon secondary to systemic sclerosis/scleroderma?* □ Yes □ No
Please provide documentation.

Has the patient received prior treatment with, and is intolerant of or resistant to, at least one calcium channel blocker?* □ Yes □ No
Please provide documentation.

Will the patient be using a calcium channel blocker on alternate days with Adcirca? □ Yes □ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

Liqrev Suspension (sildenafil)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: _____

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP – 4201
P.O. Box 64811
St. Paul, MN 55164-0811